替格瑞洛与氯吡格雷在动脉瘤血流导向装置术中的安全性、疗效及成本的多中心队列比较研究
本多中心回顾性队列比较研究纳入连续接受血流导向装置栓塞治疗的动脉瘤患者,比较替格瑞洛(50例)与氯吡格雷(53例)的安全性与疗效。两组在年龄、性别、吸烟状态、动脉瘤形态与大小、手术细节、血栓栓塞与出血并发症率、血管造影及功能结局方面均无差异,但替格瑞洛费用更高。作者结论认为替格瑞洛安全有效,但建议仅用于氯吡格雷低反应者。
要点
- 替格瑞洛组50例与氯吡格雷组53例在血栓栓塞及出血并发症率上无差异。
- 两组血管造影及功能结局无差异,但替格瑞洛费用显著高于氯吡格雷。
- 作者建议替格瑞洛保留用于氯吡格雷低反应患者。
核心结论
- 与氯吡格雷相比,替格瑞洛在血流导向装置置入后预防血栓栓塞并发症方面安全有效,但费用显著更高。
- 作者建议将替格瑞洛保留用于对氯吡格雷低反应的患者。
研究设计与样本
- 多中心、回顾性、队列比较研究设计,连续纳入接受血流导向装置栓塞治疗并接受替格瑞洛或氯吡格雷治疗的动脉瘤患者。
- 替格瑞洛组50例,氯吡格雷组53例。
主要发现
- 两组患者年龄、性别、吸烟状态、动脉瘤形态与大小及手术细节均无差异。
- 两组血栓栓塞及出血并发症率、血管造影及功能结局均无差异。
- 替格瑞洛费用高于氯吡格雷。
临床怎么用
- 作者建议替格瑞洛保留用于对氯吡格雷低反应的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thromboembolic and hemorrhagic complications are among the most feared adverse events in the endovascular treatment of aneurysms, and this is particularly the case for flow diverter devices. Dual antiplatelet therapy has become standard of care; however, the safety, efficacy, and cost profiles of newer antiplatelet agents are not well characterized in the neurovascular context. OBJECTIVE: To compare the safety, efficacy, and cost of one of these newer agents, ticagrelor, to the most frequently used agent, clopidogrel. METHODS: A multicenter, retrospective, cohort comparison study design of consecutively treated aneurysms with flow diverter embolization device and treated with either ticagrelor or clopidogrel was performed. Data were collected on patient demographics and risk factors, procedural details, antiplatelet treatment regime, complications, and angiographic and functional outcomes. RESULTS: Fifty patients undergoing flow diverter device deployment and treatment with ticagrelor were compared to 53 patients undergoing flow diversion and treatment with clopidogrel. The patients' age, sex, smoking status, aneurismal morphology and size, and procedural details did not differ between the 2 groups; neither did the rate of thromboembolic and hemorrhagic complications, angiographical, and functional outcomes. Ticagrelor was more expensive when compared to clopidogrel. CONCLUSION: Ticagrelor is a safe and effective agent for prevention of thromboembolic complications following flow diverter deployment when compared to clopidogrel. However, ticagrelor remains significantly more expensive than clopidogrel, and, thus, we would advise ticagrelor be reserved for patients who are hyporesponsive to clopidogrel.
引用
- Moore JM, Adeeb N, Shallwani H, et al. A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Neurosurgery. 2017. PMID: 28475757. doi:10.1093/neuros/nyx079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。